AAAAAA

   
Results: 1-13 |
Results: 13
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Authors: Gore, SD Weng, LJ Zhai, S Figg, WD Donehower, RC Dover, GJ Grever, M Griffin, CA Grochow, LB Rowinsky, EK Zabalena, Y Hawkins, EK Burks, K Miller, CB
Citation: Sd. Gore et al., Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia, CLIN CANC R, 7(8), 2001, pp. 2330-2339
A phase I clinical and pharmacological evaluation of sodium phenylbutyrateon an 120-h infusion schedule
Authors: Carducci, MA Gilbert, J Bowling, MK Noe, D Eisenberger, MA Sinibaldi, V Zabelina, Y Chen, TL Grochow, LB Donehower, RC
Citation: Ma. Carducci et al., A phase I clinical and pharmacological evaluation of sodium phenylbutyrateon an 120-h infusion schedule, CLIN CANC R, 7(10), 2001, pp. 3047-3055
Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas
Authors: Grossman, SA Phuphanich, S Lesser, G Rozental, J Grochow, LB Fisher, J Piantadosi, S
Citation: Sa. Grossman et al., Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas, J CL ONCOL, 19(13), 2001, pp. 3260-3266
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors
Authors: Heath, EI O'Reilly, S Humphrey, R Sundaresan, P Donehower, RC Sartorius, S Kennedy, MJ Armstrong, DK Carducci, MA Sorensen, JM Kumor, K Kennedy, S Grochow, LB
Citation: Ei. Heath et al., Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors, CANC CHEMOT, 48(4), 2001, pp. 269-274
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors
Authors: Dees, EC Whitfield, LR Grove, WR Rummel, S Grochow, LB Donehower, RC
Citation: Ec. Dees et al., A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors, CLIN CANC R, 6(10), 2000, pp. 3885-3894
A prospective pharmacologic evaluation of age-related toxicity of adjuvantchemotherapy in women with breast cancer
Authors: Dees, EC O'Reilly, S Goodman, SN Sartorius, S Levine, MA Jones, RJ Grochow, LB Donehower, RC Fetting, JH
Citation: Ec. Dees et al., A prospective pharmacologic evaluation of age-related toxicity of adjuvantchemotherapy in women with breast cancer, CANCER INV, 18(6), 2000, pp. 521-529
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
Authors: Baker, SD Diasio, RB O'Reilly, S Lucas, VS Khor, SP Sartorius, SE Donehower, RC Grochow, LB Spector, T Hohneker, JA Rowinsky, EK
Citation: Sd. Baker et al., Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil, J CL ONCOL, 18(4), 2000, pp. 915-926
Population pharmacokinetic model for topotecan derived from phase I clinical trials
Authors: Gallo, JM Laub, PB Rowinsky, EK Grochow, LB Baker, SD
Citation: Jm. Gallo et al., Population pharmacokinetic model for topotecan derived from phase I clinical trials, J CL ONCOL, 18(12), 2000, pp. 2459-2467
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: Acceptable toxicity and suggestion of improved 1-year disease-free survival
Authors: Chakravarthy, A Abrams, RA Yeo, CJ Korman, LT Donehower, RC Hruban, RH Zahurek, ML Grochow, LB O'Reilly, S Hurwitz, H Jaffee, EM Lillemoe, KD Cameron, JL
Citation: A. Chakravarthy et al., Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: Acceptable toxicity and suggestion of improved 1-year disease-free survival, INT J RAD O, 48(4), 2000, pp. 1089-1096
Clinical potential of matrix metalloprotease inhibitors in cancer therapy
Authors: Heath, EI Grochow, LB
Citation: Ei. Heath et Lb. Grochow, Clinical potential of matrix metalloprotease inhibitors in cancer therapy, DRUGS, 59(5), 2000, pp. 1043-1055
Absorption, metabolism, and excretion of C-14-temozolomide following oral administration to patients with advanced cancer
Authors: Baker, SD Wirth, M Statkevich, P Reidenberg, P Alton, K Sartorius, SE Dugan, M Cutler, D Batra, V Grochow, LB Donehower, RC Rowinsky, EK
Citation: Sd. Baker et al., Absorption, metabolism, and excretion of C-14-temozolomide following oral administration to patients with advanced cancer, CLIN CANC R, 5(2), 1999, pp. 309-317
Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion
Authors: Stevenson, JP DeMaria, D Sludden, J Kaye, SB Paz-Ares, L Grochow, LB McDonald, A Selinger, K Wissel, P O'Dwyer, PJ Twelves, C
Citation: Jp. Stevenson et al., Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion, ANN ONCOL, 10(3), 1999, pp. 339-344
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: Survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels
Authors: Abrams, RA Grochow, LB Chakravarthy, A Sohn, TA Zahurak, ML Haulk, TL Ord, S Hruban, RH Lillemoe, KD Pitt, HA Cameron, JL Yeo, CJ
Citation: Ra. Abrams et al., Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: Survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels, INT J RAD O, 44(5), 1999, pp. 1039-1046
Risultati: 1-13 |